VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. - Wikidata - awgldk - TriplyDB

VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression.

VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression.

http://www.wikidata.org/entity/Q42044757

about

STAT3 Protein Regulates Vascular Smooth Muscle Cell Phenotypic Switch by Interaction with Myocardin.Hypoxia-induced oxidative stress in ischemic retinopathy Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity Proline-rich tyrosine kinase 2 via enhancing signal transducer and activator of transcription 3-dependent cJun expression mediates retinal neovascularization Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity.STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.Protective effect of maternal uteroplacental insufficiency on oxygen-induced retinopathy in offspring: removing bias of premature birth Mechanisms and management of retinopathy of prematurity.Pathophysiology and mechanisms of severe retinopathy of prematurity.VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor.Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity.Metabolic adaptation and neuroprotection differ in the retina and choroid in a piglet model of acute postnatal hypoxia.Conditional Deletion of Smad1 Ameliorates Glomerular Injury in Progressive Glomerulonephritis Assessment of vascular regeneration in the CNS using the mouse retina.Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human.Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms.Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization.Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients.Advanced glycation end (AGE) product modification of laminin downregulates Kir4.1 in retinal Müller cells.Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery.

P2860

Q35925825-0A0D1CF2-D491-4F61-9A2A-F46D1FE95962 Q36355485-41E4DD6F-F60B-4526-B7F2-774ACDC268E6 Q36379513-10A4F123-6D94-4FD8-8141-41DFF486A574 Q36752978-7A9C1FD9-3E13-45E0-9ED9-C20C74C908EF Q36925591-87E4B8D5-AC0E-4DCA-804F-46B597FF909B Q37149035-AFE0EBA0-8CA8-4CB6-AFC0-E26D25A51F46 Q37404757-706581D6-D868-4365-ADFD-E20AD4FEF054 Q37561227-C1AE5CEF-DAFF-43D6-BA99-E27D0D3E000E Q37577214-BC4B8804-7A9B-44C1-8A00-CE1A352C0D0F Q37640165-FC1941F7-74BA-403A-8232-5A921F2F56B8 Q38069895-165980C0-11C3-41CA-8F64-CA82A76B417F Q38274655-C16C6795-BBD3-45AD-90F2-17AB6EF0BDF2 Q38560836-05333F9C-DB97-4D02-BF39-2F30F2E354D6 Q39224184-20CEFDA7-BE74-4375-9189-605BC4F5F8BE Q42081421-DFD0180D-936A-4730-A2DB-3F9B636BBCB2 Q42219273-517E6FF4-868C-44E8-A329-2B0CE4948540 Q42379900-EFEDDADA-02F1-4E50-B7CD-1B14942F72E0 Q42548814-A9DE40AF-2B66-4AD3-94AF-97DB5A960CA4 Q47758114-B09D9D1F-0E75-4782-8002-9A2959C11D49 Q47828029-469416BE-1B66-46FA-A4A5-6414D33DA3D5 Q48120672-5F6B9BE4-C58C-4D53-9608-B965AFE4A06A Q50926952-CD9E222F-2E9E-473C-B794-3E39A895F1EC Q52688316-22D8218A-F08C-4062-A0AA-CDF782296770 Q55262530-DE99204D-8496-4646-8A6F-F9304604D7AF

P2860

VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression.

http://www.wikidata.org/entity/Q42044757

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

VEGF-mediated STAT3 activation ...... cal erythropoietin expression.

@en

VEGF-mediated STAT3 activation ...... cal erythropoietin expression.

@nl

type

label

VEGF-mediated STAT3 activation ...... cal erythropoietin expression.

@en

VEGF-mediated STAT3 activation ...... cal erythropoietin expression.

@nl

prefLabel

VEGF-mediated STAT3 activation ...... cal erythropoietin expression.

@en

VEGF-mediated STAT3 activation ...... cal erythropoietin expression.

@nl

P1433

Q42044757-96F60DC1-ADBD-4180-A61F-D7E2201F981A

P1476

Q42044757-E4B519BD-2919-4662-828C-A5BDF3159851

P2093

Q42044757-02E1A86A-0434-440E-8EFE-3E16A0B62E63

Q42044757-5ECB952C-CA72-4D76-9DBD-0B73339CC07E

Q42044757-780B7AE2-DF1E-4CCF-B1DC-12E32E2E34F9

Q42044757-9303BBEC-FDB4-43BF-932F-071F3BC3D3C3

Q42044757-E61136D1-9529-4DD0-96FB-1F5ECF96A091

Q42044757-FD1048C5-CA72-448C-868B-B6AF982F9852

P2860

Q42044757-173F2434-3DC3-4DBA-B25A-FA984BD0E8CD

Q42044757-21170C68-FDE7-45A9-8D47-26ED6EADE1AF

Q42044757-229EBD17-3124-412B-BC67-D3EFE02547CD

Q42044757-238B6074-03BA-4EDA-B9CA-23D675AB8CC6

Q42044757-246606DB-2410-4228-9A0C-7EE28E84CE5C

Q42044757-39754D60-32CF-4775-B2CA-B4ABE5F060C2

Q42044757-39DC2840-CDFF-45FD-815F-830B78D442F6

Q42044757-3B3EF0FE-0C57-41A9-AB9F-D43A31BA6112

Q42044757-3F0A5844-F242-4D28-A19B-1CA8E9200412

Q42044757-3F9959C3-524C-4242-948F-DD040FDA0D61

P304

Q42044757-234F2FD7-9EBC-4773-842A-A364CB6B067A

P31

Q42044757-E1815147-3BE0-4BE2-9AFA-3E4A5B556ECE

P356

Q42044757-F04ACCC7-3A22-4E90-BD99-CDD5F8C5F549

P407

Q42044757-844D4559-C05F-496C-8BC0-011B0D109095

P433

Q42044757-EB811367-DA00-4292-A185-34CEE61F29F4

P478

Q42044757-BF1DD368-0DBA-439A-8692-268F9199E636

P577

Q42044757-24B1AF19-95C3-41D6-B1C0-544E0B87AFB4

P5875

Q42044757-85E2BB17-5A12-4476-9DA9-DBD0FE5D18A1

P698

Q42044757-0349CCFA-E20C-4252-83CF-97B79FF03016

P921

Q42044757-4A33D591-910D-4318-8B59-5AB619E276A8

P932

Q42044757-686D3002-3190-4E36-B36C-9F885A9B32DC

P356

J.AJPATH.2011.11.031

P1433

The American Journal of Pathology

P1476

VEGF-mediated STAT3 activation ...... cal erythropoietin expression.

@en

P2093

George Wesley Smith

http://www.w3.org/2001/XMLSchema#string

Grace Byfield

http://www.w3.org/2001/XMLSchema#string

Haibo Wang

http://www.w3.org/2001/XMLSchema#string

M Elizabeth Hartnett

http://www.w3.org/2001/XMLSchema#string

Manabu McCloskey

http://www.w3.org/2001/XMLSchema#string

Yanchao Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.

Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model.

Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy

Clinical implications of vascular growth factors in proliferative retinopathies.

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

Organogenesis and tumorigenesis: insight from the JAK/STAT pathway in the Drosophila eye

The JAK/STAT signaling pathway.

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.

HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin.

P304

1243-1253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJPATH.2011.11.031

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221733879

http://www.w3.org/2001/XMLSchema#string

P698

22230249

http://www.w3.org/2001/XMLSchema#string

P921

P932

3349887

http://www.w3.org/2001/XMLSchema#string